Skadden, Arps, Slate, Meagher & Flom has advised Shenyang-based 3SBio Inc. on its $712 million initial public offering in Hong Kong.
In the IPO, the Chinese biotechnology company, known for its treatments for blood disorders, sold 606.1 million shares at $1.17 each. The bulk of the proceeds will be used for acquisitions to expand the company’s product portfolio, with the remainder going toward boosting its production capacity and research and development.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
